Literature DB >> 31260731

Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes.

Alma Martinez Fernandez1, Luca Regazzoni2, Maura Brioschi3, Erica Gianazza1, Piergiuseppe Agostoni4, Giancarlo Aldini2, Cristina Banfi1.   

Abstract

Human serum albumin (HSA) is the most abundant circulating protein in the body and presents an extensive range of biological functions. As such, it is prone to undergo post-translational modifications (PTMs). The non-enzymatic early glycation of HSA, one of the several PTMs undergone by HSA, arises from the addition of reducing sugars to amine group residues, thus modifying the structure of HSA. These changes may affect HSA functions impairing its biological activity, finally leading to cell damage. The aim of this study was to quantitate glycated-HSA (GA) levels in the plasma of heart failure (HF) patients and to evaluate the biological effects of GA on HL-1 cardiomyocytes. Plasma GA content from HF patients and healthy subjects was measured by direct infusion electrospray ionization mass spectrometry (ESI-MS). Results pointed out a significant increase of GA in HF patients with respect to the control group (p < 0.05). Additionally, after stimulation with GA, proteomic analysis of HL-1 secreted proteins showed the modulation of several proteins involved, among other processes, in the response to stress. Further, stimulated cells showed a rapid increase in ROS generation, higher mRNA levels of the inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), and higher levels of the oxidative 4-HNE-protein adducts and carbonylated proteins. Our findings show that plasma GA is increased in HF patients. Further, GA exerts pro-inflammatory and pro-oxidant effects on cardiomyocytes, which suggest a causal role in the etiopathogenesis of HF.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyocytes; Glycated albumin; Inflammatory response; Oxidative stress

Year:  2019        PMID: 31260731     DOI: 10.1016/j.freeradbiomed.2019.06.023

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  10 in total

Review 1.  Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders.

Authors:  E Sally Ward; Deborah Gelinas; Erwin Dreesen; Jolien Van Santbergen; Jan Terje Andersen; Nicholas J Silvestri; Joseph E Kiss; Darrell Sleep; Daniel J Rader; John J P Kastelein; Els Louagie; Gestur Vidarsson; Isabel Spriet
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

2.  Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.

Authors:  Nitin A Das; Andrea J Carpenter; Anthony Belenchia; Annayya R Aroor; Makoto Noda; Ulrich Siebenlist; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cell Signal       Date:  2019-12-17       Impact factor: 4.315

3.  A novel 3D-printed centrifugal ultrafiltration method reveals in vivo glycation of human serum albumin decreases its binding affinity for zinc.

Authors:  Monica J Jacobs; Cody W Pinger; Andre D Castiaux; Konnor J Maloney; Dana M Spence
Journal:  Metallomics       Date:  2020-07-22       Impact factor: 4.636

Review 4.  Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases.

Authors:  Rosaria Vincenza Giglio; Bruna Lo Sasso; Luisa Agnello; Giulia Bivona; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello; Marcello Ciaccio
Journal:  J Clin Med       Date:  2020-11-11       Impact factor: 4.241

5.  Immature Circulating SP-B, Bound to HDL, Represents an Early Sign of Smoke-Induced Pathophysiological Alterations.

Authors:  Cristina Banfi; Maura Brioschi; Massimo Mapelli; Erica Gianazza; Alice Mallia; Beatrice Zoanni; Elisabetta Salvioni; Paola Gugliandolo; Nicolò Capra; Fabrizio Veglia; Piergiuseppe Agostoni
Journal:  Biomolecules       Date:  2021-04-09

6.  Prenylcysteine oxidase 1, an emerging player in atherosclerosis.

Authors:  C Banfi; R Baetta; S S Barbieri; M Brioschi; A Guarino; S Ghilardi; L Sandrini; S Eligini; G Polvani; O Bergman; P Eriksson; E Tremoli
Journal:  Commun Biol       Date:  2021-09-21

7.  Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis.

Authors:  Cristina Banfi; Patrizia Amadio; Marta Zarà; Maura Brioschi; Leonardo Sandrini; Silvia S Barbieri
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

8.  The Burden of Impaired Serum Albumin Antioxidant Properties and Glyco-Oxidation in Coronary Heart Disease Patients with and without Type 2 Diabetes Mellitus.

Authors:  Francesco Piarulli; Cristina Banfi; Maura Brioschi; Alessandra Altomare; Eugenio Ragazzi; Chiara Cosma; Giovanni Sartore; Annunziata Lapolla
Journal:  Antioxidants (Basel)       Date:  2022-07-30

Review 9.  Comprehensive overview of human serum albumin glycation in diabetes mellitus.

Authors:  Hong-Yan Qiu; Ning-Ning Hou; Jun-Feng Shi; Yong-Ping Liu; Cheng-Xia Kan; Fang Han; Xiao-Dong Sun
Journal:  World J Diabetes       Date:  2021-07-15

10.  Integrative Role of Albumin: Evolutionary, Biochemical and Pathophysiological Aspects.

Authors:  D A Belinskaia; P A Voronina; N V Goncharov
Journal:  J Evol Biochem Physiol       Date:  2021-12-20       Impact factor: 0.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.